Loading…
Develops topical therapies for rare, serious genetic skin diseases, led by a treatment for lymphatic malformations.
Develops topical therapies for rare, serious genetic skin diseases, led by a treatment for lymphatic malformations.
No product to sell yet and no revenue; it is funded by raising capital, and value rests on a topical rapamycin gel clearing its late-stage trial and FDA review for lymphatic malformations. Rare-disease drugs are sold to a small group of specialists, so launch economics rest on a small patient pool.
Moat: none (IP / patents). Addresses rare skin diseases with no approved treatments, but is clinical-stage with small target populations.
Headquarters: Wayne, Pennsylvania, US · Founded: 2015 · Employees: 29
Size Palvella Therapeutics (PVLA) is a United States Health Care company (Biotechnology) with a market value of $2.53B, the 1648th largest of 3,117 United States companies the cockpit tracks. Shares closed at $175.92 on 6 Nov 2026.
Performance Over six months the shares gained 45.0%, against -9.1% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 20 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +4.1%).
Short interest Short interest is 16.7% of the free float (15 Oct 2026).
Next results Next results expected around 5 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $25.9M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | $0 | $0 | $0 | $0 | $23.1M |
| EBITDA | -$57.7M | -$38.6M | -$14.1M | -$11.9M | -$40.7M |
| Net income | -$61.7M | -$41.7M | -$17.4M | $18.7M | -$33.3M |
| Free cash flow | -$36.5M | -$25.0M | -$10.8M | -$13.7M | -$61.0M |
| Capital expenditure | $0 | $0 | $0 | $0 | $1.04M |
| Total debt | $22.6M | $18.4M | $11.9M | $78.7M | $13.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Palvella Therapeutics PVLA | $2.53B | +45% | -100% | n/a | n/a | n/a |
| Krystal Biotech KRYS | $8.92B | -2% | +26% | 48% | 17.1× | 11.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PVLA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +33.9% | -0.3% | 4th highest of 21 |
| 6-month return | +45.0% | -9.1% | 6th highest of 20 |
| Distance from 52-week high | -0.6% | -33.2% | 2nd highest of 21 |
| Revenue growth (TTM) | -100.0% | +4.1% | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | 67.9× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | 17.1× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | 22.6× | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | 21.9× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 10.3× | 31.3% | -3.8% |
| Beam Therapeutics BEAM | United States | $2.73B | -18% | +163% | -268% | 13.2× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 4.7× | 0.5% | +36.0% |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 8.8× | 33.3% | +70.2% |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 5.7× | -0.8% | +64.6% |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | 6.1× | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |